此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer

Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer

A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国
        • 招聘中
        • Tianjin Medical University Cancer Institute & Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Informed Consent Form (ICF) .
  • Aged 18 to 70 years (inclusive) at the time of signing the ICF.
  • Cytology or pathology confirmed Patients with pancreatic tumors.

Cohort 1:

  • The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
  • Adjuvant chemotherapy completed, as determined by the investigator.

Cohort 2:

  • Disease progression after prior standard systemic antitumor therapy for the current disease stage;
  • Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
  • No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
  • For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.

Cohort 3:

  • Patients receiving standard chemotherapy regimens include, but are not limited to:

    • the oFOLFIRINOX regimen;
    • gemcitabine combined with nab-paclitaxel; or
    • other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
  • Patients receiving targeted therapy must meet all the following criteria:

    • Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
    • The investigator determines that no contraindications exist for the proposed targeted therapy.
  • ECOG score of 0 ~1 .

  • Expected survival time is more than 12 weeks.

  • Negative blood pregnancy test for females of childbearing potential is required.

Exclusion Criteria:

  • Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
  • History of bone marrow or organ transplantation;
  • History of other primary malignancies;
  • Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
  • Patients with a known allergy to any component of the study drugs.
  • History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
  • Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
  • Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
  • Clinically significant thyroid dysfunction as assessed by the investigator.
  • Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
  • Clinically significant cardiovascular diseases.
  • Insufficient bone marrow reserve or insufficient organ function.
  • Female subjects who are pregnant or breastfeeding.
  • Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
  • The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:队列 1

Combination with Adjuvant Chemotherapy

实验性的:队列 2

GKPTZ-01

实验性的:队列 3

Combination with Chemotherapy or Targeted Therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Recurrence-Free Survival
大体时间:2 years

6 months RFS(recurrence-free survival) rate(cohort 1)

2 years
Objective response rate
大体时间:2 years

Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3)

2 years

次要结果测量

结果测量
措施说明
大体时间
Disease Control Rate(DCR)
大体时间:2 years

Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01

2 years
Duration of Response(DOR)
大体时间:2 years

Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier

2 years
Progression-free Survival(PFS)
大体时间:2 years

Time from GKPTZ-01 treatment to disease progression or death

2 years
Overall survival(OS)
大体时间:2 years

Time from GKPTZ-01 treatment to death

2 years
Adverse events
大体时间:2 years

The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events).

2 years
Patient Quality of Life
大体时间:2 years

EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30)

2 years

其他结果措施

结果测量
措施说明
大体时间
Pharmacokinetic
大体时间:2 years

Levels of T-cell Receptor copies

2 years
Biomarker
大体时间:2 years

Concentration levels of serum cytokines, tumor markers

2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月2日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2029年7月1日

研究注册日期

首次提交

2026年11月13日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅